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S998 Journal of Thoracic Oncology Vol. 13 No. 10Sof side effects associated with pain control devices and early discon-
tinuation due to side effects were analyzed. Result: The mean value of
NPIS on the day of surgery was 6.04 ± 2.56 in the epidural PCA group,
4.75 ± 2.35 in the IV-PCA group, and 5.27 ± 1.87 in the On-Q group and
there was no statistically significant difference. NPIS values were
decreased in all three groups until 48 hours postoperatively, but there
was no significant difference between groups. The incidence of side ef-
fects related to pain control devices up to 48 hours after operation was
the highest in the IV-PCA group (36.1%, 13/36), in the epidural PCA
group (35.7%, 10/28) and in the On-Q group (10.0%, 3/30) and there
was statistically significance (p¼0.032). The rate of early discontinuation
of the pain control device due to side effects was 33.3% (12/36) in the
IV-PCA group, 25.0% (7/28) in the epidural PCA group, and 6.7% (2/30)
in the On-Q group (p ¼ 0.032). Conclusion: The effects of pain control
after VATs lobectomy in NSCLC patients were not significantly different
in epidural-PCA, IV-PCA, and On-Q but On-Q was superior in terms of
side effects and early discontinuation of pain control device. Continuous
extrapleural infusion of local anesthetic via On-Q has less systemic side
effects and higher procedural stability than PCA. Therefore, On-Q may be
sufficient to replace PCA in pain control after VATs lobectomy in NSCLC
patients. Keywords: NSCLC, Pain control, VATS
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Background: Bone related disease is increasingly a problem as lung
cancer patients are usually older and the survival rate is increasing.
Also cancer patients with multiple chronic comorbidities are at risk of
osteoporosis (T-score of  -2.5). The purpose of the study is to
investigated the risk factors that attribute to osteoporosis of patients
with lung cancer. Method: We retrospectively investigated the inci-
dence of osteoporosis of lung cancer patients from March, 2017 to April
2018. A total of 124 patients who were diagnosed with lung cancer at
one tertiary academic hospital underwent bone mineral density test.
Result: Among the 124 patients, 40 (32.3%) showed osteoporosis.
Alcohol history, smoking history, lung cancer histology, lung cancer
stage, bone metastasis, and comorbidity (hypertension, diabetes, cor-
onary artery disease, cerebrovascular accident, and chronic obstructive
pulmonary disease) did not differ significantly among the osteoporosis
and normal group . In univariate analysis, age (P ¼ 0.025), BMI (P ¼
0.028), and female (P < 0.001) were statistically significant. In multi-
variate logistic regression analysis, age (OR: 1.070, 95% CI:1.016-1.126,
p ¼ 0.01), BMI (OR: 0.840, 95% CI:0.738-0.956, p ¼ 0.008), and female
(OR: 0.142, 95% CI:0.055-0.366, p < 0.001) were also statistically
significant. Conclusion: One-third of lung cancer patients were diag-
nosed with osteoporosis at a high rate. Old age, low BMI and female sex
were the risk factors affecting osteoporosis of lung cancer patients.
Physicians should be aware to of screening bone marrow density of
lung cancer patients with old age, low BMI and female group. Studies
on the effect of calcium supply and bisphosphonate treatment on bone
metastasis and fracture in these osteoporosis patients are underway.
Keywords: osteoporosis, Female, lung cancer
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Background: Advanced cancer patients frequently experience high-
distressing symptoms which could not be relieved with standardoncological treatment even can be refractory to intensive palliative
care. For these cases, palliative sedation or decrease patient’s con-
sciousness below certain level (ramsay score 4 or more) is well defined
but not well standardized procedure for intractable symptoms of
cancer patients. Method: The patients included into this study in
consecutive way without any exception from November 2014 to August
2017. There were 82 patients (90.0%) and 9 patients (10.0%) with
NSCLC and SCLC, respectively. Palliative sedation protocol is consisted
of midazolam /morphine (30 mg/24 hr). For the effectiveness of the
palliative sedation, we accept taregt RSS score of 4 for the immediate
and elective patients. Result: There were 62 and 29 patients electively
or urgently sedated. Median age of patients in elective and immediate
sedation were 61.5 and 63, respectively. Additionally, main etiologies
for the refractory symptoms were dyspnea, delirium and intractable
pain in 44 (71.0%) vs 3 (4.8%), 15 (24.2%) vs 16 (55.2%), and 6
(20.7%) vs 7 (24.1) patients for the elective and immediate sedation
groups. There was no statistically significant difference between two
groups with regard to sex, age and main reasons for the palliative
sedation. Duration of palliative sedation were 0.59 days in immediate
group whereas this time significantly longer in elective group with 4.7
days (p<0.01). Time between last chemotherapy and start of the
palliative sedation were 82.3 vs 119.0 days in elective and immediate
group, respectively. In elective sedation group, target score of R4 was
achieved in 32 (51.6%) patients whereas in immediate sedation group
score of R4 was significantly lower than elective group and achieved in
only 3 (10.3%) patients, respectively (p<0.01). Dose of 30-30 mg/24-
hour IV MaM infusion was perfectly enough for the immediate sedation
group , 60-60 mg and 90-90 MaM infusions were required in 10
(16.1%) and 5 (8.1%) patients for target RS. Adverse events were seen
in 18 (29%) and 7 (24.1%) patients in elective and immediate group,
respectively. Hypotension was the most prominent adverse event in
both groups. Conclusion: Palliative sedation is effective way of con-
trolling intractable symptoms. Most common reason for palliative
sedation was progressive dyspnea in lung cancer for both groups. 30-
30 mg/24-hour IV MaM starting dose well tolerated and highly effec-
tive dose, 15/15 mg dose increment can be done if needed. Keywords:
lung cancer, palliative sedation, immediate or elective, intractable
symptom
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Background: Published reports of first-line afatinib treatment efficacy,
side-effects and resistance mechanism in the real-world setting are
lacking. Method: A retrospective observational study of patients with
EGFR mutant advanced non-small cell lung cancer (NSCLC) receiving
first-line afatinib in University Malaya Medical Center from 1st
December 2014 to 30th April 2018. Result: Twenty-two of 33 patients
on first-line afatinib were eligible for analysis. The patients’ de-
mographic and clinical characteristics are as shown in Table 1. The
mPFS was 14.3 months, overall response rate was 86.3% (19/22) and
disease control rate was 95.5% (21/22). The median time-to-treatment
failure was 16.2 months. The median overall survival has not been
reached but 12-month survival rate was 81.8% (18/22). A patient with
exon 18 G719X and exon 20 S768I mutation had received treatment for
23.3 months without disease progression (PD). The PFS of a patient
with exon 20 insertion was 9 months and of another patient with exon
18 G719X and exon 20 T790M mutations was 4.4 months. Of patients
with brain metastases, the PFS of 2 patients treated with stereotactic
October 2018 Abstracts S999radiosurgery (SRS) was 15.9 months and 9 months, respectively while
that of a patient who had whole brain radiotherapy (WBRT) and a
patient who underwent debulking surgery only was 16.5 months and
2.6 months, respectively. The incidence of side-effects was rash 90.1%
(20/22), stomatitis 63.3% (14/22), paronychia 72.7% (16/22), and
diarrhea 77.3% (17/22). One (4.5%) patient each had grade 3 diarrhea
and cutaneous lesions. Of 17 patients with PD, 2 (11.8%) had PD in the
brain. T790M mutation was detected in 62.2% (8/13) patients who
underwent repeat biopsy. Conclusion: Afatinib is an effective treat-
ment of EGFR-mutant advanced NSCLC. When combined with SRS or
WBRT, afatinib conferred good PFS in patients with symptomatic brain
metastases. Severe side effects are uncommon and T790M mutation
was the commonest resistance mechanism. Keywords: Real-world
data, afatinib, T790M mutation
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Background: The analysis of risk-adjusted outcome is beneficial for
quality assessment in surgery as well as preoperative risk stratification.
Eurolung risk models are recently reported, large population-based
prediction tools of cardiopulmonary morbidity and mortality in pa-
tients who underwent anatomic lung resection. This study is aimed to
evaluate validity of the models in a Japanese population.Method: From
2007 to 2014, 637 anatomic lung resections were performed in our
institution. Patients who had induction therapy (n¼23) and with
missing data (n¼2) were excluded from the analysis, and requisite
variables (age, sex, body mass index, predicted postoperative forced
expiratory volume in 1 s, coronary artery disease, cerebrovascular
disease, chronic kidney disease, thoracotomy approach, extendedresections, operation of pneumonectomy) were examined. Cardiopul-
monary morbidity and 30-day mortality rates were estimated by
Eurolung risk models according to the formula for computation (Bru-
nelli A, et al. European risk models for morbidity (EuroLung1) and
mortality (EuroLung2) to predict outcome following anatomic lung
resections: an analysis from the European Society of Thoracic Surgeons
database. Eur J Cardiothorac Surg, 2017; 51: 490-497). Aggregated
Eurolung risk scores were also calculated, and patients with similar
risk were classified into plural groups. These results were compared
with observed outcomes. In addition, we analyzed long term outcomes
of the groups using the Kaplan-Meier method. Result: Surgical pro-
cedures included 9 pneumonectomies, 15 bilobectomies, 483 lobec-
tomies, and 105 segmentectomies. Cardiopulmonary complications of
any grade were occurred in 137 cases; this rate was lower than pre-
dicted by Eurolung1 (22.4% vs. 28.4%). Within 30 days after operation,
4 fatal cases were experienced, which was significantly lower than
expected by Eurolung2 (0.7% vs. 6.9%). Morbidity rate was clearly
stratified by Eurolung1 aggregate score as 0% (n¼0, score 0-1), 14.7%
(n¼11, score 2-4), 18.6% (n¼30, score 5-7), 21.3% (n¼46, score 8-11),
34.5% (n¼49, score 12-16), and 33.3% (n¼1, score 17-19). Stratifi-
cation of mortality rate by Eurolung2 aggregate score also developed
apparent trend, although the observed number of death was quite
small: 0% (score 0-3), 0% (score 4-6), 1.2% (score 7-8), 1.5% (score 9-
11), 4.8% (score 12-14), and 0% (score 15-17). The Higher (8-19)
Eurolung1 aggregate score group showed poor 5-year overall survival
compared with the lower (0-7) score group (72.3% vs. 90.4%, P<0.01).
Conclusion: Eurolung risk models did not completely match with the
morbidity and mortality in our institution. On the other hand, Euro-
lung1 aggregate score was useful to predict not only morbidity, but also
long term outcomes. Keywords: risk model, lung cancer, Surgery
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Background: The internet, through social media, blogs and forums, has
enabled patients to share experiences and outcomes. Data mining and
crowdsourcing is a methodological approach to gather the individual
experiences within these platforms and convert them into Real World
Evidence (RWE) that can help patients make decisions, especially in the
case of new treatments or treatments in trial. This abstract is a case
study of how this methodology was used to inform the decision be-
tween Whole Brain Radiation (WBR) vs. osimertinb in treating brain
metastasis in EGFR+, t790M, NSCLC e at a time when the results to an
open label trial were pending. Method: The methodology identified
trusted sources and similar profiled patients. The steps: 1. Identify
reputable on-line sources by referrals. 2. Crowdsource peers with same
tumour group, staging, gene sequence and treatment path. 3. Analyze
results and patient feedback of treatments A search identified 46 lung
cancer blogs and 4 cancer forums. Inspire.com was then chosen as the
crowdsourcing target as it had over 39,000 lung cancer patients
registered. Result: The search found 470 posts on osimertinib in
clinical trial; 66 discussions on brain lesions and osimertinib were
accessible from the search. Conversations with patients of the same
genetic profiles, metastasis and treatments were selected. The user
profiles detailed clinical histories, which increased the trust factor of
the data. Information was obtained from April to June 2016 with data
points beginning in 2014. When reviewing the 66 self-reported cases, it
was found that osimertinib was effective in patients with brain me-
tastases in 36% of patients while 4% had no response. Quality of life
and side effects were other fields that were explored. This evidence
influenced the patient to choose osimertinib instead of WBR to treat
her lung cancer. Conclusion: The Internet offers opportunities to
